SIGA Technologies Inc. - 10-Q Summary (Period Ended Sept 30, 2009)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for SIGA Technologies, Inc., a bio-defense company focused on developing products against biological warfare agents (e.g., smallpox, Arenaviruses) and novel anti-infectives. The reporting period covers the three and nine months ended September 30, 2009. The company has no commercially approved products and relies on government grants, contracts, and equity financing to fund operations.
Key Financial Metrics
| Metric | 9 Months Ended Sept 30, 2009 | 9 Months Ended Sept 30, 2008 |
|---|---|---|
| Revenues | $9,856,674 | $5,577,055 |
| Operating Expenses | $18,006,581 | $11,766,534 |
| Operating Loss | $(8,149,907) | $(6,189,479) |
| Net Loss | $(18,666,301) | $(7,027,921) |
| Net Loss Per Share (Basic/Diluted) | $(0.51) | $(0.20) |
| Cash and Cash Equivalents (End of Period) | $1,442,256 | $2,957,755 |
| Net Cash Used in Operating Activities | $(6,350,157) | $(6,396,105) |
| Net Cash Provided by Financing Activities | $5,774,608 | $2,810,909 |
| Total Liabilities | $19,659,383 | $7,242,701 |
| Stockholders' Equity (Deficit) | $(11,494,069) | $1,554,599 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 77% year-over-year to $9.9 million, driven primarily by expanded NIH grants and contracts supporting the lead drug candidate ST-246.
- Expense Increases: Operating expenses rose 53% to $18.0 million. Research and Development (R&D) expenses increased 49% to $12.2 million due to higher manufacturing and clinical testing costs for ST-246. Selling, General, and Administrative (SG&A) expenses increased 73% to $5.4 million, largely due to higher legal/litigation support and stock-based compensation.
- Net Loss Expansion: The net loss more than doubled to $18.7 million. This was significantly impacted by a $10.5 million non-cash loss recorded due to the increase in the fair value of common stock warrants (classified as liabilities under ASC 815).
- Liquidity Position: Cash balances decreased by approximately $879,000 during the period. However, the company raised $5.8 million through financing activities, including $2.5 million from a related party investment commitment (MacAndrews & Forbes) and proceeds from warrant exercises.
- Balance Sheet Impact: Total liabilities increased significantly due to the reclassification and fair value adjustment of stock warrants, resulting in a shift from positive equity to a stockholders' deficit of $11.5 million.
Guidance, Outlook, and Risks
- Outlook: Management believes existing cash, combined with proceeds from the MacAndrews & Forbes investment commitment (with $5.5 million remaining available) and anticipated government grants, will support operations beyond the next twelve months.
- Recent Grants: In September 2009, the company received a $1.7 million grant from NIAID for bunyavirus inhibitors and a $3.0 million Phase II grant from NIH for ST-246 development.
- Key Risks:
- Going Concern: The company has incurred cumulative losses and has no approved products. Future operations depend on securing additional financing and government contracts.
- Legal Proceedings: Ongoing litigation with PharmAthene, Inc. regarding ST-246 licensing. The company cannot estimate a range of potential loss at this time.
- Regulatory Compliance: The company recently remediated a compliance issue regarding the submission of audited statements to the HHS Office of Inspector General.
- Market Volatility: Significant fluctuations in the fair value of warrants continue to impact reported net income/loss.
Investor Verification Checklist
- Verify the status and potential financial impact of the PharmAthene, Inc. v. SIGA Technologies, Inc. litigation.
- Confirm the remaining availability and terms of the $5.5 million investment commitment from MacAndrews & Forbes.
- Monitor the progress of the BARDA Request for Proposal (RFP) for the purchase of 1.7 million courses of ST-246.
- Assess the sustainability of the cash burn rate given the current cash balance of $1.4 million and reliance on future grants.
- Review the impact of ASC 815 on future earnings, specifically regarding the fair value adjustments of warrant liabilities.